Boston Scientific (BSX) Expected to Post Earnings on Wednesday

Boston Scientific (NYSE:BSX) will likely be posting its Q3 2026 results before the market opens on Wednesday, October 28th. Analysts expect the company to announce earnings of $0.7180 per share and revenue of $5.06 billion for the quarter. Boston Scientific has set its Q3 2026 guidance at 0.800-0.820 EPS and its FY 2026 guidance at 3.280-3.320 EPS. Interested persons may review the information on the company’s upcoming Q3 2026 earnings report page for the latest details on the call scheduled for Wednesday, October 28, 2026 at 8:00 AM ET.

Boston Scientific (NYSE:BSX) last announced its earnings results on Wednesday, July 29th. The medical equipment provider reported $0.86 EPS for the quarter, topping the consensus estimate of $0.83 by $0.03. The business had revenue of $5.44 billion during the quarter, compared to analysts’ expectations of $5.38 billion. Boston Scientific had a net margin of 17.50% and a return on equity of 19.28%. The firm’s revenue was up 7.5% on a year-over-year basis. During the same quarter in the prior year, the company posted $0.75 earnings per share. On average, analysts expect Boston Scientific to post $3.24 EPS for the current fiscal year and $3.36 EPS for the next fiscal year.

Boston Scientific Stock Down 0.2%

Boston Scientific stock opened at $45.60 on Tuesday. The company has a market cap of $66.08 billion, a P/E ratio of 18.46, a price-to-earnings-growth ratio of 1.10 and a beta of 0.58. Boston Scientific has a 1-year low of $41.38 and a 1-year high of $105.65. The company has a fifty day simple moving average of $45.54 and a 200 day simple moving average of $58.24. The company has a current ratio of 1.24, a quick ratio of 0.74 and a debt-to-equity ratio of 0.43.

Analyst Upgrades and Downgrades

Several equities research analysts have commented on BSX shares. Wall Street Zen cut shares of Boston Scientific from a “buy” rating to a “hold” rating in a research report on Sunday, August 2nd. The Goldman Sachs Group reduced their price objective on shares of Boston Scientific from $71.00 to $57.00 and set a “buy” rating for the company in a research note on Tuesday, July 14th. Royal Bank Of Canada decreased their price objective on Boston Scientific from $85.00 to $70.00 and set an “outperform” rating for the company in a report on Thursday, July 30th. Evercore lowered their target price on Boston Scientific from $65.00 to $52.00 and set an “outperform” rating on the stock in a research report on Wednesday, October 7th. Finally, Oppenheimer lowered their target price on Boston Scientific from $85.00 to $65.00 and set an “outperform” rating on the stock in a research report on Monday, September 21st. One investment analyst has rated the stock with a Strong Buy rating, twenty-five have given a Buy rating, three have given a Hold rating and two have assigned a Sell rating to the stock. According to data from MarketBeat, Boston Scientific presently has an average rating of “Moderate Buy” and an average price target of $68.07.

Insider Buying and Selling

In other Boston Scientific news, Director Edward J. Ludwig acquired 5,000 shares of the company’s stock in a transaction on Friday, July 31st. The shares were purchased at an average price of $45.48 per share, for a total transaction of $227,400.00. Following the completion of the purchase, the director directly owned 30,359 shares of the company’s stock, valued at approximately $1,380,727.32. This represents a 19.72% increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Michael F. Mahoney acquired 186,240 shares of the business’s stock in a transaction dated Monday, August 3rd. The stock was acquired at an average cost of $48.33 per share, with a total value of $9,000,979.20. Following the completion of the transaction, the chief executive officer owned 1,590,024 shares of the company’s stock, valued at approximately $76,845,859.92. The trade was a 13.27% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Over the last 90 days, insiders acquired 194,522 shares of company stock worth $9,385,210. Company insiders own 0.34% of the company’s stock.

About Boston Scientific

Boston Scientific Corporation is a medical technology company that develops, manufactures and markets devices used to diagnose and treat a broad range of complex medical conditions. Founded in 1979 and headquartered in Marlborough, Massachusetts, the company serves healthcare providers and patients worldwide.

Its products support minimally invasive procedures in areas including interventional cardiology, peripheral interventions, electrophysiology, endoscopy, urology and neuromodulation.